| Bioactivity | STAT3-IN-12 is a potent STAT3 signal inhibitor that can inhibit IL-6 induced JAK/STAT3 signalling pathway activation. STAT3-IN-12 inhibits cancer cell growth, migration, and induce cell apoptosis as well as cycle arrest. STAT3-IN-12 can be used in cancer-related research, such as hepatocellular carcinoma (HCC) and oesophageal carcinoma[1]. | ||||||||||||
| Invitro | STAT3-IN-12 (compound 24, 0-10 μM approximately, 72 h) inhibits cancer cell growth and migration in HepG2 and EC109 cells[1].STAT3-IN-12 (0-20 μM, 16 h) binds to the STAT3 protein and inhibits IL-6-mediated STAT3 phosphorylation, also inhibts STAT3 nuclear localization and dimerization in EC109 and HepG2 cells[1].STAT3-IN-12 (0-20 μM, 48 h) induces cell apoptosis as well as cycle arrest in HepG2 and EC109 cells[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| Name | STAT3-IN-12 | ||||||||||||
| Formula | C28H30N4O2 | ||||||||||||
| Molar Mass | 454.56 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|